Substantially Improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO). An international randomized phase III trial

Autor: A Jager, M Jongen-Lavrencic, JP Lotz, A Gonçalves, M Graeser, U Nitz, IAM Mandjes, MJ Holtkamp, M Schot, VP Retel, EJ Kuip, ANM Wymenga, IR Konings, VCG Tjan-Heijnen, JR Kroep, CP Schrӧder, E Van Der Wall, Sc Linn, S Vliek

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3389d18e6873ca9ee30fb022f95fc593

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.

Autor: Vliek S; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Hilbers FS; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Mandjes I; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kessels R; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kleiterp S; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lips EH; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Mulder L; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kayembe MT; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Russell NS; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Vrancken Peeters MTFD; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Surgery, Amsterdam University Medical center, Amsterdam, The Netherlands., Holtkamp MJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schot M; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Baars JW; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Honkoop AH; Department of Internal Medicine, Isala Klinieken, Zwolle, The Netherlands., Vulink AJE; Division of Medical Oncology, Reinier de Graaf Hospital, Delft, The Netherlands., Imholz ALT; Department of Internal Medicine, Deventer Ziekenhuis, Deventer, The Netherlands., Vrijaldenhoven S; Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands., van den Berkmortel FWPJ; Department of Oncology, Zuyderland Medisch Centrum, Heerlen-Geleen, The Netherlands., Meerum Terwogt JM; Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands., Schrama JG; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands., Kuijer P; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van der Padt-Pruijsten A; Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands., Wesseling J; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Gilhuijs KGA; Image Sciences Institute, University Medical Center Utrecht, Utrecht, Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Nederlof P; Department of Molecular diagnostics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Linn SC; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.linn@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.linn@nki.nl.; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. s.linn@nki.nl.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2023 Sep 09; Vol. 9 (1), pp. 75. Date of Electronic Publication: 2023 Sep 09.

The effectiveness of chlorhexidine-silver sulfadiazine impregnated central venous catheters in patients receiving high-dose chemotherapy followed by peripheral stem cell transplantation.

Autor: Maaskant JM; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. j.m.maaskant@planet.nl, De Boer JP, Dalesio O, Holtkamp MJ, Lucas C

Publikováno v: European journal of cancer care [Eur J Cancer Care (Engl)] 2009 Sep; Vol. 18 (5), pp. 477-82.

Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience.

Autor: Schrama JG; Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. j.schrama@nki.nl, Holtkamp MJ, Baars JW, Schornagel JH, Rodenhuis S

Publikováno v: British journal of cancer [Br J Cancer] 2003 Jun 16; Vol. 88 (12), pp. 1831-8.

Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.

Autor: Schrama JG; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2001 Jul; Vol. 28 (2), pp. 173-80.